Nowe możliwości hamowania infekcji B. anthracis

• Autorzy: Zakowska D. , Bartoszcze M. , Niemcewicz M. , Bielawska-Drozd A.

Warianty tytułu

EN

New methods of inhibiting B. anthracis infections

• Języki publikacji: PL

Abstrakty

To date, antibiotics have been the primary drugs used in the treatment of anthrax infections. However, their effectiveness is questionable, especially during the phase of intensive toxin production in the course of infection, and the number of drug-resistant strains continues to rise. Successful treatment of anthrax infection is therefore becoming more difficult. The article discusses some of the new methods of inhibiting anthrax infections: the inhibition of spore germination and of the attachment of PA to the host cell receptor, the inhibition of the enzymatic process of cleaving PA into PA63 and PA20, and of PA63 oligomerization, endocytosis and translocation (their influence on the protection of macrophages against lysis was also discussed). In addition, the neutralization of B. anthracis LeTx and EdTx toxins was presented as another potential method of inhibiting anthrax infections.

Słowa kluczowe

PL

zagrozenia zdrowia; choroby zakazne; terroryzm biologiczny; bakterie; laseczki waglika; Bacillus anthracis; infekcja bakteryjna; hamowanie; przetrwalniki bakteryjne; kielkowanie; toksyna waglikowa; neutralizacja

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2011
• Tom: 67
• Numer: 10
• Opis fizyczny: s.665-668,bibliogr.

Twórcy

autor

Zakowska D.

• Ośrodek Diagnostyki i Zwalczania Zagrożeń Biologicznych, Wojskowy Instytut Higieny i Epidemiologii w Puławach, ul.Lubelska 2, 24-100 Puławy

autor

Bartoszcze M.

autor

Niemcewicz M.

autor

Bielawska-Drozd A.

Bibliografia

• 1. Akoachere M., Squires R. C., Nour A. M., Angelov L., Brojatsch J., Abel-Santos E. V.: Identification of an in vivo inhibitor of Bacillus anthracis Sterne spore germination. J. Biol. Chem. 2007, 282, 12112-12118.
• 2. Albrecht M. T., Li H., Williamson E. D., LeButt Ch. S., Flick-Smith H. C., Quinn C. P., Westra H., Galloway D., Mateczun A., Goldman S., Groen H., Baillie L. W. J.: Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 2007, 75, 5425-5433.
• 3. Alvarez Z., Abel-Santos E.: Potential use of inhibitors of bacteria spore germination in the prophylactic treatment of anthrax and Clostridium difficile-associated disease. Expert Rev. Anti. Infect. Ther. 2007, 5, 783-792.
• 4. Buczek J., Gliński Z., Buczek K., Kostro K., Święcicka I.: Wąglik. Post. Mikrobiol. 2002, 41, 339-350.
• 5. Cathelineau A. M de., Bokoch G. M.: Peptide inhibitors MAP the way towards fighting anthrax pathogenesis. J. Biochem. 2006, 395, 1-3.
• 6. Chapelsky S., Batty S., Frost M., Mogridge J.: Inhibition of anthrax lethal toxininduced cytolysis of RAW264.7 cells by celastrol. PLoS ONE 2008, 1, 1421, 1-7.
• 7. Crawford M. A., Zhu Y., Green C. S., Burdick M. D., Sanz P., Alem F., O'Brien A. D., Mehrad B., Strieter R. M., Hughes M. A.: Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli. Infect. Immun. 2009, 77, 1664-1678.
• 8. Cui X., Moayeri M., Li Y., Li X., Haley M., Fitz Y., Correa-Araujo R., Banks S. M., Leppla S. H., Eichacker P. Q.: Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286, 699-709.
• 9. Gimenez A. P., Wu Y.-Z., Paya M., Delclaux Ch., Touqui L., Goossens P. L.: High bactericidal efficiency of type IIA phospholipase A2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J. Immunol. 2004, 173, 521-530.
• 10. Goldman M. E., Cregar L., Nguyen D., Simo O., O'Malley S., Humphreys T.: Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol. 2006, 6, 1-8.
• 11. Karginov V. A., Nestorovich E. M., Moayeri M., Leppla S. H., Bezrukov S. M.: Blocking anthrax lethal toxin at the protective antigen channel by using structure inspired drug design. PNAS. 2005, 102, 15075-15080.
• 12. Komiyama T., Swanson J. A., Fuller R. S.: Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. Antimicrob. Agents Chemother. 2005, 49, 3875-3882.
• 13. Manayani D. J., Thomas D., Dryden K. A., Reddy V., Siladi M. E., Marlett J. M., Rainey G. J. A., Pique M. E., Scobie H. M., Yeager M., Young J. A. T., Manchester M., Schneemann A.: A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathogens 2007, 3, 1422-1431.
• 14. Moayeri M., Wiggins J. F., Lindeman R. E., Leppla S. H.: Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. 2006, 50, 2658-2665.
• 15. Rivera J., Nakouzi A., Abboud N., Revskaya E., Goldman D., Collier R. J., Dadachova E., Casadevall A.: A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 2006, 74, 4149-4156.
• 16. Sanchez A. M., Thomas D., Gillespie E. J., Damoiseaux R., Rogers J., Saxe J. P., Huang J., Manchester M., Bradley K. A.: Amidarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob. Agents Chemother. 2007, 51, 2403-2411.
• 17. Scobie H. M., Thomas D., Marlett J. M., Destito G., Wigelsworth D. J., Collier R. J., Young J. A. T., Manchester M.: A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 2005, 192, 1047-1051.
• 18. Shen Y., Zhukovskaya N. L., Zimmer M. I., Soelaiman S., Bergson P., Wang Chyung-Ru., Gibbs C. S., Tang Wei-Jen.: Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatisis B virus infection. PNAS. 2004, 101, 3242-3247.
• 19. Soelaiman S., Wei Binqing Q., Bergson P., Lee Y.-S., Shen Y., Mrksich M., Shoichet B. K., Tang W.-J.: Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997.
• 20. Wang J. Y., Roehrl M. H.: Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Medical Immunol. 2005, 4, 1-8.